Breakthrough therapies like Sarepta Therapeutics' (SRPT) Elevidys and Novartis AG's (NVS) Zolgensma demonstrate remarkable efficacy, but analysts caution that their multimillion-dollar price tags—amplified by expanding R&D pipelines—pose affordability challenges for employers and insurers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments